AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11765597 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial immunostimulant (Symbioflor 1, cells and autolysate of human Enterococcus faecalis)
Number of subjects: 136
Study 9293232 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation procedures
Number of subjects: 60
Study 9293232 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation procedures plus explicit attributional retraining
Number of subjects: 60
Study 9293232 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 9293232 — intervention group
Group type: COMPARATOR
Intervention: Normally achieving students (additional control group)
Number of subjects: 60
Study 8446670 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.15, 0.3, or 0.45 mg/kg
Number of subjects: 14
Study 8446670 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.01, 0.02, or 0.04 mg/kg
Number of subjects: 14
Study 8446670 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (various doses)
Number of subjects: 14
Study 2949169 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (1 mg daily, titrated to double every two weeks)
Number of subjects: 8
Study 2949169 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (8 weeks treatment)
Number of subjects: 8
Study 2949169 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 8
Study 2949169 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two week phase)
Number of subjects: 8
Study 29764246 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional sodium stibogluconate (SSG)
Number of subjects: 188
Study 29764246 — intervention group
Group type: COMPARATOR
Intervention: Intralesional metronidazole
Number of subjects: 188
Study 29468770 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 133
Study 29468770 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 133
Study 26910854 — intervention group
Group type: EXPERIMENTAL
Intervention: Terrain (experimental attention training game)
Number of subjects: 31
Study 26910854 — intervention group
Group type: COMPARATOR
Intervention: Tetris (control game)
Number of subjects: 31
Study 24518180 — intervention group
Group type: EXPERIMENTAL
Intervention: IDeg 200 U/mL
Number of subjects: 373
Study 24518180 — intervention group
Group type: COMPARATOR
Intervention: IDeg 100 U/mL
Number of subjects: 373
Study 22983778 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated intravenous norepinephrine (NE) infusion
Number of subjects: 4
Study 20075533 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood removal (10% of estimated blood volume for Hb > 12g%, 7% for Hb < 12g%)
Number of subjects: 188
Study 20075533 — intervention group
Group type: COMPARATOR
Intervention: Control group (no autologous blood removal)
Number of subjects: 188
Study 18042473 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate inhalation solution 20 microg BID via nebulizer (FFIS)
Number of subjects: 351
Study 18042473 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate 12 microg BID via dry powder inhaler (FA)
Number of subjects: 351
Study 18042473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 16091265 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit condition with semantically studied words
Number of subjects: 0
Study 16091265 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit condition with deep encoding
Number of subjects: 0
Study 16091265 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit task
Number of subjects: 0
Study 16091265 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit task with awareness
Number of subjects: 0
Study 16091265 — intervention group
Group type: COMPARATOR
Intervention: Control words in implicit task
Number of subjects: 0
Study 12131114 — intervention group
Group type: EXPERIMENTAL
Intervention: PMP-membrane oxygenators
Number of subjects: 24
Study 12131114 — intervention group
Group type: COMPARATOR
Intervention: PPL-membrane oxygenators
Number of subjects: 24
Study 9924160 — intervention group
Group type: EXPERIMENTAL
Intervention: c7E3 (abciximab)
Number of subjects: 2099
Study 9924160 — intervention group
Group type: COMPARATOR
Intervention: Control (no abciximab)
Number of subjects: 2099
Study 7762533 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) for 6 months
Number of subjects: 12
Study 7762533 — intervention group
Group type: COMPARATOR
Intervention: healthy control subjects
Number of subjects: 12
Study 2271205 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 micrograms/kg of prostaglandin E1
Number of subjects: 30
Study 2271205 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 micrograms/kg of prostaglandin E1
Number of subjects: 30
Study 2271205 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study 7397293 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 30
Study 7397293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31775403 — intervention group
Group type: EXPERIMENTAL
Intervention: Parasagittal interlaminar (PIL) approach
Number of subjects: 65
Study 31775403 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal (TF) approach
Number of subjects: 65
Study 31775403 — intervention group
Group type: COMPARATOR
Intervention: Midline interlaminar (MIL) approach
Number of subjects: 65
Study 29931459 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3, 70 µg (2800 IU)/day for three months
Number of subjects: 81
Study 29931459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 27368021 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency thermocoagulation at 62°C
Number of subjects: 1354
Study 27368021 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency thermocoagulation at 65°C
Number of subjects: 1354
Study 27368021 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency thermocoagulation at 68°C
Number of subjects: 1354
Study 27368021 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency thermocoagulation at 62°C, 65°C, and 68°C
Number of subjects: 1354
Study 24439641 — intervention group
Group type: EXPERIMENTAL
Intervention: Body acupuncture
Number of subjects: 0
Study 24439641 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenglong method
Number of subjects: 0
Study 24439641 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 22521904 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 67
Study 22521904 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 67
Study 19923079 — intervention group
Group type: EXPERIMENTAL
Intervention: Coopdech endobronchial blocker tube (BB)
Number of subjects: 36
Study 19923079 — intervention group
Group type: COMPARATOR
Intervention: Double-lumen endobronchial tube (DLT)
Number of subjects: 36
Study 17846932 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin only (IO)
Number of subjects: 52
Study 17846932 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime insulin with sulphonylurea (IS)
Number of subjects: 52
Study 17846932 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime insulin with metformin (IM)
Number of subjects: 52
Study 15353978 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 19
Study 15353978 — intervention group
Group type: COMPARATOR
Intervention: No Mycophenolate mofetil (Control)
Number of subjects: 19
Study 12187213 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 500 mg oral dose of levofloxacin
Number of subjects: 400
Study 12187213 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional doses of levofloxacin for high-risk patients
Number of subjects: 400
Study 10542974 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate (FP) 2000 micrograms daily via Diskhaler
Number of subjects: 395
Study 10542974 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (BUD) 2000 micrograms daily via Turbuhaler
Number of subjects: 395
Study 7606904 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback and reasoning explanation during training sessions
Number of subjects: 0
Study 7606904 — intervention group
Group type: COMPARATOR
Intervention: Feedback alone during training sessions
Number of subjects: 0
Study 7606904 — intervention group
Group type: COMPARATOR
Intervention: Feedback with no reasoning explanation during training sessions
Number of subjects: 0
Study 2132162 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroxyacetone (DHP)
Number of subjects: 7
Study 112550 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 50
Study 112550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31813273 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCAP program (8 hr of training in practice guidelines and brief therapeutic skills for depression, anxiety, ADHD, and behavioral disorders)
Number of subjects: 76
Study 31813273 — intervention group
Group type: COMPARATOR
Intervention: Control group (practiced as usual)
Number of subjects: 76
Study 31585489 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramide-containing moisturizer
Number of subjects: 24
Study 31585489 — intervention group
Group type: COMPARATOR
Intervention: Hydrophilic cream
Number of subjects: 24
Study 28371223 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 32
Study 28371223 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump therapy
Number of subjects: 32
Study 25968058 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind subjects (congenital and acquired)
Number of subjects: 66
Study 25968058 — intervention group
Group type: COMPARATOR
Intervention: Sighted controls
Number of subjects: 66
Study 25968058 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital blindness
Number of subjects: 66
Study 25968058 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquired blindness
Number of subjects: 66
Study 23351277 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen elixir (10-15 mg/kg)
Number of subjects: 30
Study 23351277 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen suppository (10-15 mg/kg)
Number of subjects: 30
Study 21069379 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen for 45 min
Number of subjects: 10
Study 21069379 — intervention group
Group type: COMPARATOR
Intervention: Medical air for 45 min
Number of subjects: 10
Study 19477353 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin daily for 12 weeks
Number of subjects: 47
Study 19477353 — intervention group
Group type: COMPARATOR
Intervention: 10 mg atorvastatin daily for 12 weeks
Number of subjects: 47
Study 16451147 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% oxygen in nitrogen and saline 2 ml intravenously (i.v.) at the end of surgery (group 80)
Number of subjects: 90
Study 16451147 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% oxygen in nitrogen and saline 2 ml intravenously (i.v.) at the end of surgery (group 30)
Number of subjects: 90
Study 16451147 — intervention group
Group type: COMPARATOR
Intervention: 30% oxygen in nitrogen and ondansetron 4 mg (group O)
Number of subjects: 90
Study 16451147 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% oxygen in nitrogen and saline 2 ml intravenously (i.v.) (group 80)
Number of subjects: 90
Study 15648986 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 35
Study 15648986 — intervention group
Group type: COMPARATOR
Intervention: Tenoxicam
Number of subjects: 35
Study 15225176 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day rabeprazole-based treatment (rabeprazole 20 mg b.d., amoxicillin 1000 mg b.d., clarithromycin 500 mg b.d.)
Number of subjects: 803
Study 15225176 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day rabeprazole-based treatment (rabeprazole 20 mg b.d., amoxicillin 1000 mg b.d., clarithromycin 500 mg b.d.)
Number of subjects: 803
Study 15225176 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day rabeprazole-based treatment (rabeprazole 20 mg b.d., amoxicillin 1000 mg b.d., clarithromycin 500 mg b.d.)
Number of subjects: 803
Study 15225176 — intervention group
Group type: COMPARATOR
Intervention: 10-day omeprazole-based treatment (omeprazole 20 mg b.d., amoxicillin 1000 mg b.d., clarithromycin 500 mg b.d.)
Number of subjects: 803
Study 10408450 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel IOLs
Number of subjects: 90
Study 10408450 — intervention group
Group type: COMPARATOR
Intervention: Polymethyl methacrylate IOLs
Number of subjects: 90
Study 10408450 — intervention group
Group type: COMPARATOR
Intervention: Silicone IOLs
Number of subjects: 90
Study 7747846 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital capacity breath
Number of subjects: 35
Study 7747846 — intervention group
Group type: COMPARATOR
Intervention: Tidal breathing
Number of subjects: 35
Study 2286005 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine 25 mg/kg + Pyrimethamine 1.25 mg/kg as a single dose (S + P)
Number of subjects: 69
Study 2286005 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine 10 + 10 + 5 mg/kg over three days with Sulfadoxine + Pyrimethamine on the third day (A + S + P)
Number of subjects: 69
Study 7015798 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg once a day)
Number of subjects: 48
Study 7015798 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa (250 mg thrice a day)
Number of subjects: 48
Study 31204680 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopy before in-vitro fertilisation
Number of subjects: 0
Study 31204680 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 27930383 — intervention group
Group type: EXPERIMENTAL
Intervention: E-OJ-01 (400 mg for 56 days)
Number of subjects: 32
Study 27930383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 26361063 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 6505
Study 26361063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6505
Study 24057202 — intervention group
Group type: COMPARATOR
Intervention: 0 % (FBP)
Number of subjects: 70
Study 24057202 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 % SAFIRE
Number of subjects: 70
Study 24057202 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 % SAFIRE
Number of subjects: 70
Study 24057202 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 % SAFIRE
Number of subjects: 70
Study 24057202 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 % SAFIRE
Number of subjects: 70
Study 24057202 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 % SAFIRE
Number of subjects: 70
Study 24057202 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 % to 50 % SAFIRE
Number of subjects: 70
Study 21860289 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone followed by misoprostol
Number of subjects: 260
Study 21860289 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol alone
Number of subjects: 260
Study 19794330 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol or Risperidone
Number of subjects: 70
Study 19794330 — intervention group
Group type: COMPARATOR
Intervention: Atypical antipsychotics
Number of subjects: 70
Study 17952657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabinoids (specifically Sativex®)
Number of subjects: 0
Study 17952657 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of cannabinoids
Number of subjects: 0
Study 15266762 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted hatching
Number of subjects: 207
Study 15266762 — intervention group
Group type: COMPARATOR
Intervention: Control (no assisted hatching)
Number of subjects: 207
Study 11531898 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine diagnosis based on IHS criteria
Number of subjects: 1668
Study 11531898 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative criteria for migraine (including attacks < 4 h and > 72 h)
Number of subjects: 1668
Study 11531898 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician diagnosis of migraine
Number of subjects: 1668
Study 11531898 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean attack frequency
Number of subjects: 1668
Study 11531898 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean attack duration
Number of subjects: 1668
Study 11531898 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict IHS criteria for migraine
Number of subjects: 1668
Study 11531898 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative criteria for migraine
Number of subjects: 1668
Study 9753208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sang‐35
Number of subjects: 36
Study 9753208 — intervention group
Group type: COMPARATOR
Intervention: Neoral
Number of subjects: 36
Study 7924177 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (2 gm per day for 22 weeks)
Number of subjects: 37
Study 7924177 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive drugs only (Control for subgroup A1)
Number of subjects: 37
Study 7924177 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (2 gm per day for 10 weeks)
Number of subjects: 37
Study 7924177 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive drugs only (Control for subgroup A2)
Number of subjects: 37
Study 29205608 — intervention group
Group type: EXPERIMENTAL
Intervention: In-utero aspiration (IUA)
Number of subjects: 61
Study 29205608 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 61
Study 26793952 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual thrombus aspiration
Number of subjects: 152
Study 26793952 — intervention group
Group type: COMPARATOR
Intervention: Control (no thrombus aspiration)
Number of subjects: 152
Study 24050787 — intervention group
Group type: EXPERIMENTAL
Intervention: Free school fruit arrangement (receiving one free fruit or vegetable per day)
Number of subjects: 1423
Study 24050787 — intervention group
Group type: COMPARATOR
Intervention: No school fruit arrangement
Number of subjects: 1423
Study 22538532 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 500 mg/d
Number of subjects: 5
Study 22538532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 20826169 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-rich supplements (n=12)
Number of subjects: 16
Study 20826169 — intervention group
Group type: COMPARATOR
Intervention: Control group (isocaloric combination of carbohydrate and fat supplements, n=4)
Number of subjects: 16
Study 18229988 — intervention group
Group type: EXPERIMENTAL
Intervention: QPR training
Number of subjects: 249
Study 16823511 — intervention group
Group type: EXPERIMENTAL
Intervention: DPPE (tesmilifene) plus doxorubicin (DOX)
Number of subjects: 271
Study 16823511 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (DOX) alone
Number of subjects: 271
Study 15055026 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgisis ES mesh
Number of subjects: 20
Study 15055026 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene mesh
Number of subjects: 20
Study 11049908 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine-15 group (3 mL of 1.5% lidocaine containing 15 microg of epinephrine)
Number of subjects: 80
Study 11049908 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine-10 group (2 mL of 1.5% lidocaine containing 10 microg of epinephrine)
Number of subjects: 80
Study 11049908 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine-5 group (1 mL of 1.5% lidocaine containing 5 microg of epinephrine)
Number of subjects: 80
Study 11049908 — intervention group
Group type: COMPARATOR
Intervention: Saline group (3 mL of normal saline IV)
Number of subjects: 80
Study 8922195 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine (VRB) at a dose of 25 mg/m2 weekly
Number of subjects: 204
Study 8922195 — intervention group
Group type: COMPARATOR
Intervention: Vindesine (VDS) at a dose of 3 mg/m2 weekly
Number of subjects: 204
Study 8922195 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine (VRB) followed by VDS + cisplatin (P)
Number of subjects: 204
Study 8922195 — intervention group
Group type: COMPARATOR
Intervention: Vindesine (VDS) followed by VRB + cisplatin (P)
Number of subjects: 204
Study 8922195 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine (VRB)
Number of subjects: 204
Study 8922195 — intervention group
Group type: COMPARATOR
Intervention: Vindesine (VDS)
Number of subjects: 204
Study 1395657 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal tube feeding
Number of subjects: 38
Study 1395657 — intervention group
Group type: COMPARATOR
Intervention: Gastric tube feeding
Number of subjects: 38
Study 2859900 — intervention group
Group type: COMPARATOR
Intervention: Almitrine (3 mg X kg‐1)
Number of subjects: 40
Study 2859900 — intervention group
Group type: COMPARATOR
Intervention: Almitrine (1.5 mg X kg‐1 X day‐1) for four weeks
Number of subjects: 40
Study 31555389 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (LTRA)
Number of subjects: 0
Study 31555389 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 0
Study 31555389 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD)
Number of subjects: 0
Study 30091061 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/d)
Number of subjects: 30
Study 30091061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 27530618 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential information checklist
Number of subjects: 631
Study 27530618 — intervention group
Group type: COMPARATOR
Intervention: Unstructured counselling
Number of subjects: 631
Study 24894625 — intervention group
Group type: EXPERIMENTAL
Intervention: NicVAX
Number of subjects: 558
Study 24894625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 558
Study 24894625 — intervention group
Group type: EXPERIMENTAL
Intervention: Top 30% antibody responders with NicVAX
Number of subjects: 558
Study 24894625 — intervention group
Group type: COMPARATOR
Intervention: Top 30% antibody responders with Placebo
Number of subjects: 558
Study 22722614 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (Transcutaneous Electrical Nerve Stimulation)
Number of subjects: 79
Study 22722614 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 79